Skip to content
Dx

ICD-10-CM 2027 diagnosis code

E16.3Increased secretion of glucagon

✓ Billable / specific

E16.3 is a valid, billable ICD-10-CM code for increased secretion of glucagon. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About E16.3

E16.3 is the ICD-10-CM diagnosis code for increased secretion of glucagon. It belongs to category E16 (other disorders of pancreatic internal secretion), block E15-E16 (other disorders of glucose regulation and pancreatic internal secretion) and chapter 4 (endocrine, nutritional and metabolic diseases). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within E16 (other disorders of pancreatic internal secretion), E16.3 is specifically for increased secretion of glucagon. Related codes cover drug-induced hypoglycemia without coma (E16.0), other hypoglycemia (E16.1), hypoglycemia, unspecified (E16.2), increased secretion of gastrin (E16.4), other specified disorders of pancreatic internal secretion (E16.8), disorder of pancreatic internal secretion, unspecified (E16.9) and hypoglycemia level (E16.A).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 643 (Endocrine Disorders with MCC, relative weight 1.6139), DRG 644 (Endocrine Disorders with CC, relative weight 1.0044) and DRG 645 (Endocrine Disorders without CC/MCC, relative weight 0.7459), in MDC 10 (Endocrine, Nutritional and Metabolic Diseases and Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 251.4 (abnormality of secretion of glucagon).

Coding notes

Applicable toConditions and synonyms classified to this code
  • Hyperplasia of pancreatic endocrine cells with glucagon excess

Notes that apply from higher levels

Instructions written at a parent level also apply to E16.3.

Broader instructions also apply from Chapter 4: Endocrine, nutritional and metabolic diseases.

Alphabetic index entries

6 entries

Terms in the official ICD-10-CM index that lead to E16.3.

Codes whose notes reference E16.3

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

ICD-9-CM equivalent

Converter →
  • 251.4Abnormality of secretion of glucagonexact

From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
  • No changes since FY2016.

Common questions about E16.3

Is E16.3 billable?

Yes. E16.3 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can E16.3 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict E16.3 as a principal diagnosis.

Is E16.3 a CC or MCC?

No. E16.3 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does E16.3 group to?

E16.3 is used in the MS-DRG v44.0 logic for MS-DRG 643 (Endocrine Disorders with MCC), MS-DRG 644 (Endocrine Disorders with CC) and MS-DRG 645 (Endocrine Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

What is the ICD-9 code for E16.3?

The CMS General Equivalence Mappings map E16.3 to ICD-9-CM 251.4.